BOSTON--(BUSINESS WIRE)--Leerink Partners, a leading healthcare investment bank, announced today the addition of Daina Graybosch, Ph.D. to the firm’s Equity Research team. Dr. Graybosch joins the firm as a Managing Director and Senior Research Analyst within the Therapeutics team. In this role, Dr. Graybosch will be leading the firm’s Immuno-oncology research efforts and will be located in the firm’s New York office.
Dr. Graybosch joins Leerink Partners from McKinsey & Company where she was most recently a Senior Expert and Head of McKinsey’s Center for Asset Optimization, as well as the U.S. Head of the McKinsey Cancer Center. In these roles, Dr. Graybosch developed several McKinsey solutions that bring data and advanced analytics to pharmaceutical development decisions. In her 11 years at McKinsey, Dr. Graybosch developed a rich understanding of oncology through her work with companies across the value chain, including Pharmaceutical, Diagnostic, Academic Medical Center, and Genomic/Data. Dr. Graybosch earned a Ph.D. in Chemistry and Chemical Biology from Harvard University and dual B.S. degrees in Biology and Chemistry from the University of Utah.
John L. Sullivan, CFA, Senior Managing Director of Equity Research and Healthcare Investment Strategist at Leerink Partners stated, “We welcome Daina and her rich understanding of oncology drug development to Leerink Partners. We are excited to have assembled a Therapeutics Research team that will deliver market-leading analysis of the fundamentals and opportunities in the biopharmaceutical industry.”
“Daina’s experience in therapeutics makes her a valuable addition to our team,” stated Geoffrey Porges, MBBS, Director of Therapeutics at Leerink Partners. “She brings unique expertise, having worked on many projects in oncology and across different aspects of pharmaceutical discovery and development. Daina’s technical and industry experience will complement the skills of our other analysts and bring unique investable insights to our clients.”
“I am excited to join Leerink Partners,” stated Dr. Graybosch. “With unprecedented options for investment in oncology and beyond, Leerink will be positioned to deliver research with unique depth backed by our analysts’ experience and leading analytics.”
About Leerink Partners
Leerink Partners LLC is a leading investment bank, specializing in healthcare. Our knowledge, experience and focus enable us to help our clients define and achieve their strategic, capital markets and investment objectives. We partner with companies that develop and commercialize innovative products and services that are defining the future of healthcare. Leerink Partners LLC is a member of FINRA/SIPC. For more information, please visit: www.leerink.com.
